Jul. 2 at 5:57 PM
Citizens reiterated
$CRNX Market Outperform-
$90.
$NBIX $CORT $IMVT $BBIO ARGX VRDN AMGN TRML RGLS - NVS VRTX
Citizens said in its note:
"Crinetics (
$CRNX, MO,
$90 PT) will present Phase 2 TouCAHn data for atumelnant in congenital adrenal hyperplasia (CAH) during the oral session "All About
Congenital Adrenal Hyperplasia and Adrenal Insufficiency" on Saturday, July 12.
While the abstract remains embargoed, previously released data show the once-daily oral ACTH antagonist induces rapid and sustained reductions of androstenedione and 17- hydroxyprogesterone over 12 weeks, with most patients normalizing A4 within two weeks (our coverage here).
Importantly, atumelnant had greater A4 reductions than Neurocrine's (
$NBIX, NC) approved drug Crenessity, which could translate to greater glucocorticoid (GC) reductions (the regulatory endpoint).
$CRNX will also present two posters on reductions in adrenal volume and 11-oxygenated androgens in the Phase 2 trial.
Citizens goes on to say:
